Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
      • CDMO Intelligence
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Bioarctic

Evaluate

Thumbnail
May 03, 2023

Donanemab delivers for Lilly

Pivotal data on the Alzheimer’s project beat expectations, raising hopes for a swift reimbursement U-turn.

January 09, 2023

Eisai learns from Biogen’s Aduhelm disaster

Leqembi's accelerated approval sees Eisai upholding its part of the bargain, setting a reasonable price and moving fast with confirmatory data.

Article image
Vantage logo
November 30, 2022

CTAD 2022 – lecanemab data hold up, with a big but

Keenly awaited results reveal no smoking gun, but lecanemab’s modest activity appears not that different from Aduhelm’s.

Article image
Vantage logo
November 15, 2022

Morphosys suffers most from gantenerumab fallout

Article image
Vantage logo
October 18, 2022

Roche sets the gantenerumab expectations

Graduate 1 and 2 data are “not yet in house”, but a pooled analysis beckons in the event of one study failing.

Article image
Vantage logo
October 13, 2022

Few safe havens surface in another down quarter for biopharma

Lilly, Daiichi and Vertex are on track to be 2022’s best performing stocks, as the Covid crash continues.

Article image
Vantage logo
September 29, 2022

The Alzheimer's stocks riding on lecanemab's coat tails

Article image
Vantage logo
September 28, 2022

Lecanemab can; now the wait for details begins

Eisai is rewarded for doubling down on lecanemab with an apparent win that endorses 20 years of research.

Article image
Vantage logo
December 31, 2021

Biopharma developments over the Christmas period

Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.

Article image
Vantage logo
December 02, 2021

Novartis gets in on alpha-synuclein

Article image
Vantage logo
July 28, 2021

AC Immune backs alpha-synuclein despite recent setbacks

The group’s purchase of Affiris’s Parkinson’s portfolio comes after stumbles from Roche/Prothena and Biogen.

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up